Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- NANEXA.ST
- Price
- 1.30
- Stock movement up
- +- (%)
- Company name
- Nanexa AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 176.13M
- Ent value
- 178.04M
- Price/Sales
- 6.61
- Price/Book
- 2.13
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 3.68%
- 1 year return
- 63.89%
- 3 year return
- -22.97%
- 5 year return
- -29.13%
- 10 year return
- -
Last updated: 2025-04-15
DIVIDENDS
NANEXA.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 6.61 |
| Price to Book | 2.13 |
| EV to Sales | 6.68 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 135.70M |
| EPS (TTM) | -0.47 |
| FCF per share (TTM) | -0.38 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 26.66M |
| Gross profit (TTM) | -32.91M |
| Operating income (TTM) | -65.43M |
| Net income (TTM) | -64.42M |
| EPS (TTM) | -0.47 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | -123.42% |
| Operating margin (TTM) | -245.43% |
| Profit margin (TTM) | -241.64% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 19.01M |
| Net receivables | 0.00 |
| Total current assets | 35.87M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 103.47M |
| Accounts payable | 4.35M |
| Short/Current long term debt | 1.25M |
| Total current liabilities | 18.80M |
| Total liabilities | 20.92M |
| Shareholder's equity | 82.56M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -21.69M |
| Capital expenditures (TTM) | 30.51M |
| Free cash flow (TTM) | -52.20M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -78.03% |
| Return on Assets | -62.26% |
| Return on Invested Capital | -78.03% |
| Cash Return on Invested Capital | -63.23% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.30 |
| Daily high | 1.42 |
| Daily low | 1.30 |
| Daily Volume | 327K |
| All-time high | 15.20 |
| 1y analyst estimate | 3.30 |
| Beta | 1.79 |
| EPS (TTM) | -0.47 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 15 May 2025 |
Downside potential
Loading...
Downside potential data
| NANEXA.ST | S&P500 | |
| Current price drop from All-time high | -91.46% | -12.04% |
| Highest price drop | -96.01% | -56.47% |
| Date of highest drop | 26 Apr 2024 | 9 Mar 2009 |
| Avg drop from high | -54.17% | -11.07% |
| Avg time to new high | 138 days | 12 days |
| Max time to new high | 1088 days | 1805 days |
COMPANY DETAILS
Marketcap
176.13M
Marketcap category
Small-cap
Description
Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia; NEX-20 for the treatment of multiple myeloma; and NEX-22 for the treatment of type 2 diabetes. Nanexa AB (publ) was founded in 2007 and is based in Uppsala, Sweden.
Employees
19
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
As European markets react to higher-than-expected U.S. trade tariffs, with major indices like the STOXX Europe 600 experiencing their largest drop in five years, investors are reassessing their strate...
April 11, 2025
As February 2025 unfolds, the European market is marked by cautious optimism amidst ongoing geopolitical developments and trade policy shifts. Despite these uncertainties, investors continue to explor...
February 28, 2025